Welcome to our dedicated page for Stoke Therapeutics news (Ticker: STOK), a resource for investors and traders seeking the latest updates and insights on Stoke Therapeutics stock.
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company that develops RNA-based medicines to restore protein expression in severe genetic diseases. Its news flow is closely tied to the progress of its antisense oligonucleotide programs, particularly zorevunersen for Dravet syndrome and STK-002 for Autosomal Dominant Optic Atrophy (ADOA).
Investors following STOK news can expect regular updates on clinical development milestones. These include announcements on the global Phase 3 EMPEROR study of zorevunersen in children and adolescents with Dravet syndrome, multi-year data from open-label extension studies, and analyses comparing treated patients with natural history data. Stoke also reports on natural history research such as the FALCON study in ADOA, which informs the design of interventional trials like the OSPREY Phase 1 study of STK-002.
Regulatory and collaboration developments are another important category of news. Stoke highlights regulatory designations for zorevunersen, including orphan drug, rare pediatric disease, and Breakthrough Therapy Designation, as well as its strategic collaboration with Biogen, under which the companies jointly advance zorevunersen for Dravet syndrome with defined regional commercialization rights.
Corporate and financial updates appear in press releases and are often paired with SEC filings. These items cover quarterly financial results, cash runway commentary, stock-based inducement grants under Nasdaq Listing Rule 5635(c)(4), and participation in major healthcare and investor conferences. Webcasts and conference calls for analysts and investors are also announced through news releases.
For anyone researching STOK, the news stream provides context on how Stoke Therapeutics is advancing its TANGO antisense platform, executing clinical trials in rare neurological and ophthalmic diseases, and managing its partnerships and capital to support ongoing development.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Stoke Therapeutics (Nasdaq: STOK) has received authorization from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 1/2 clinical trial (OSPREY) for STK-002, targeting autosomal dominant optic atrophy (ADOA), a rare inherited optic nerve disorder causing vision loss. The study aims to assess the safety and efficacy of STK-002, designed to upregulate OPA1 protein expression and potentially halt vision deterioration. Enrollment for the trial is expected to begin in early 2024. Currently, there are no approved treatments for ADOA, affecting approximately 1 in 30,000 people globally. Stoke's approach leverages the TANGO platform, focusing on treating haploinsufficiencies and CNS diseases.
Stoke Therapeutics (NASDAQ: STOK) announced that the FDA has approved a higher single dose of STK-001 (70mg) for the Phase 1/2a MONARCH study targeting children and adolescents with Dravet syndrome. This study, which aims to evaluate the safety and efficacy of STK-001, complements ongoing assessments in the ADMIRAL trial. Dravet syndrome is a severe genetic epilepsy affecting quality of life, with current treatments inadequate for most patients. Data from the new dose cohort is expected to be released in the second half of 2023, with the company aiming for a Phase 3 trial initiation in 2024.
Stoke Therapeutics (Nasdaq: STOK) announced progress in its STK-001 trials for Dravet syndrome, expecting to complete Phase 1/2a studies in 2023 and initiate Phase 3 in 2024. The company will deliver safety and efficacy data from various dosing cohorts throughout 2023. Financially, Stoke reported revenue of $12.4 million for 2022, a net loss of $101.1 million, and increased R&D expenses totaling $77.8 million. Stoke's cash reserves stand at $230.2 million, projected to fund operations until the end of 2025, supporting the advancement of STK-001 and STK-002.
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology firm focused on treating severe diseases by enhancing protein expression through RNA-based therapies. The company will participate in two upcoming investor conferences: the Cowen 43rd Annual Health Care Conference on March 6, 2023, at 12:50 p.m. ET, and the 2nd Annual Needham Virtual Neuroscience Forum on March 15, 2023, at 3:20 p.m. ET. Live webcasts and replays will be accessible on Stoke's investor website. Stoke is known for its proprietary TANGO technology and is developing treatments for conditions like Dravet syndrome and autosomal dominant optic atrophy (ADOA). More details can be found on their website.
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology firm focused on upregulating protein expression with RNA-based therapies, will present at the virtual SVB Securities Global Biopharma Conference on February 14, 2023, at 4:20 p.m. ET. This presentation will be in a fireside chat format and will be webcast live, available on Stoke's website for 30 days post-event. Stoke's lead compound, STK-001, targets Dravet syndrome, a severe genetic epilepsy, while STK-002 is under development for autosomal dominant optic atrophy. The company is headquartered in Bedford, Massachusetts, with operations in Cambridge, Massachusetts.